Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total Other Products Sales by Quarter
Total Other Products Sales ($M) ($M)
Gilead Sciences Total Other Products Sales: $161M in Q2 2026, down 20.3% from a year earlier. That is the lowest of the 27 quarters on record here.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-06) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total Other Products Sales
- Total Other Products Sales — U.S. sales ($M)26 · Q2 2026
- Total Other Products Sales — Europe sales ($M)55 · Q2 2026
- Total Other Products Sales — Rest of World sales ($M)80 · Q2 2026
- AmBisome (liposomal amphotericin B — systemic antifungal) ($M)110 · Q2 2026
- Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M)51 · Q2 2026
- Letairis (ambrisentan — pulmonary arterial hypertension, legacy breakout) ($M)36 · Q4 2023
- Ranexa (ranolazine — chronic angina, legacy breakout) ($M)5 · Q4 2021
- Zydelig (idelalisib — hematologic oncology, legacy breakout) ($M)12 · Q4 2021
Cite this data
StockData. (2026). Gilead Sciences Total Other Products Sales ($M), quarterly Q4 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/other-prod-total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.